Foliente R L, Wise G R, Collen M J, Abdulian J D, Chen Y K
Department of Medicine, Loma Linda University Medical Center, California, USA.
Am J Gastroenterol. 1995 Dec;90(12):2160-3.
To compare the efficacy of ColoCARE Self-Test pads against Hemooccult II SENSA, a traditional guaiac-based card test, in the screening for colorectal neoplasia.
Prospective crossover analysis of 102 high-risk patients for screening of colorectal neoplasia with fecal occult blood testing, using ColoCARE Self-Test pads and Hemoccult II SENSA cards.
Sixty-eight of the 102 patients (67%) had colorectal lesions diagnosed at colonoscopy. Of this group, 55 patients (81%) had either a polyp or cancer diagnosed at colonoscopy, with 13 of these 55 patients having polyps > or = 1 cm. ColoCARE detected 21% of all lesions, compared with 72% for Hemoccult II SENSA. ColoCARE detected only 16% of cases involving either a cancer or a polyp, and 24% of cases involving either a cancer or polyp > or = 1 cm in size. This compares with 75% and 95%, respectively, for Hemoccult II SENSA. Significantly more patients preferred ColoCARE (84%) to Hemoccult II SENSA (5%) (p < 0.00001), and patients found it easier to use ColoCARE (p < 0.01). However, 33% of patients did not feel comfortable interpreting the ColoCARE results, and 29% found it difficult to interpret the color change.
These results indicate that patients may prefer the simplicity and convenience of ColoCARE; however, the test is not sensitive for the detection of colorectal neoplasia. Furthermore, patients do not feel comfortable interpreting ColoCARE results and prefer to have fecal occult blood testing interpreted by medical personnel.
比较ColoCARE自检试纸与传统基于愈创木脂的卡片检测法Hemooccult II SENSA在结直肠肿瘤筛查中的效果。
对102例结直肠肿瘤筛查高危患者进行前瞻性交叉分析,使用ColoCARE自检试纸和Hemoccult II SENSA卡片进行粪便潜血检测。
102例患者中有68例(67%)在结肠镜检查中被诊断为结直肠病变。在这组患者中,55例(81%)在结肠镜检查中被诊断为息肉或癌症,其中55例中有13例息肉直径≥1 cm。ColoCARE检测出所有病变的21%,而Hemoccult II SENSA为72%。ColoCARE仅检测出16%的癌症或息肉病例,以及24%的直径≥1 cm的癌症或息肉病例。相比之下,Hemoccult II SENSA分别为75%和95%。明显更多的患者更喜欢ColoCARE(84%)而非Hemoccult II SENSA(5%)(p<0.00001),且患者发现ColoCARE使用起来更简便(p<0.01)。然而,33%的患者对解读ColoCARE结果感到不自在,29%的患者觉得难以解读颜色变化。
这些结果表明患者可能更喜欢ColoCARE的简单便捷;然而,该检测方法对结直肠肿瘤的检测并不敏感。此外,患者对解读ColoCARE结果感到不自在,更倾向于由医务人员解读粪便潜血检测结果。